Category: bowel
-
Teva jumps sharply on bowel disease drug results
•
Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa The stock price opened 20% higher on Wall Street after the Israeli company announced positive results from the phase 2 clinical trial of Docavitog, which it is developing with Sanofi, to treat ulcerative colitis (UC) and Crohn’s disease (CD).…
-
Eli Lilly to buy bowel disease drug developer Morphic for $3.2 billion By Reuters
•
(Reuters) – Eli Lilly and Company said on Monday it will acquire Morphek Holdings Inc (NASDAQ:MLS) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for a type of inflammatory bowel disease. Shares of drug developer Morphek surged 76% to $56.15 premarket after Lilly’s offer…